CASP3 and prostate cancer: All of the prostate cancer derived cell lines showed a significant increase in caspase 3 activity when treated with 60 μM HXR9 for two hours (3.7 fold for PC3 cells and 4.8 fold for both DU145 and LNCaP cells), whilst WPMY-1 cells do not (1.4 fold increase, p = 0.0972).